Related Experiment Video
Updated: Jun 2, 2026
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug
Giuseppina Improta1, Angela Zupa, Helen Fillmore
1I.R.C.C.S. Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy.
Abstract:
Brain metastases are the most common fatal complication of systemic cancer, especially of lung (40-50%) and breast (20-30%) cancers. In this era of personalized therapy, there is a critical need to uncover the signaling architecture of brain metastases; however, little is known about what signaling pathways are activated in the context of the brain microenvironment. Using a unique study set of 42 brain metastases from patients with breast or nonsmall cell lung cancer (NSCLC), the phosphorylation/activation states of 128 key signaling proteins involved in cancer signaling were measured in laser capture microdissected tumor epithelium using reverse phase protein microarray (RPMA) technology. Distinct pathway activation subgroups from both breast and lung metastases were underpinned by, among others, ERBB2, AKT, mTOR, EGFR, SMAD, and ERK-p38 signaling. Breast cancer metastases showed significantly (p < 0.05) higher activation of the c-ERBB2/IGFR-AKT pathway network compared to NSCLC metastases, whereas NSCLC metastases to the brain exhibited higher relative levels of many members of the EGFR-ERK signaling network. Protein pathway activation mapping using RPMA revealed both the heterogeneity of signaling networks in brain metastases that would require a prior stratification to targeted therapies as well as the requirement of direct analysis of the metastatic lesion.
Insights
This study mapped signaling pathways in brain metastases from breast and lung cancers. Findings reveal distinct pathway activations, highlighting the need for personalized therapy based on metastatic lesion analysis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Brain metastases are the most common fatal complication of systemic cancers, particularly breast and lung cancers.
- Understanding the signaling pathways activated within the brain microenvironment is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the signaling architecture of brain metastases from breast and non-small cell lung cancer (NSCLC).
- To identify distinct signaling pathway activations in brain metastases to inform personalized therapy strategies.
Main Methods:
- Utilized reverse phase protein microarray (RPMA) technology to measure phosphorylation/activation states of 128 key signaling proteins.
- Analyzed laser capture microdissected tumor epithelium from 42 brain metastases (breast and NSCLC).
Main Results:
- Identified distinct pathway activation subgroups involving ERBB2, AKT, mTOR, EGFR, SMAD, and ERK-p38 signaling in brain metastases.
- Breast cancer metastases showed significantly higher activation of the c-ERBB2/IGFR-AKT pathway compared to NSCLC metastases.
- NSCLC metastases exhibited higher relative levels of EGFR-ERK signaling network members.
Conclusions:
- RPMA revealed significant heterogeneity in signaling networks within brain metastases.
- Direct analysis of metastatic lesions is essential for stratifying patients to appropriate targeted therapies.
